Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as linifanib
ABT-869 · 3 trials · 2 indications
Blood samples for the pharmacokinetics (PK) of linifanib will be collected at designated time points and assayed.
To assess the effect of rifampin on the pharmacokinetics of linifanib and metabolite(s), an analysis will be performed for the natural logarithms of Cmax and AUC of linifanib and metabolite(s) with concentrations that permit confident determination of values of the pharmacokinetic variables. A paired t-test will be performed to compare the central value on Study Day 13 (with rifampin) to that on Study Day 1 (without rifampin). Point estimates and 90% confidence intervals will also be provided.
Blood samples for the PK of ABT-869 and ketoconazole will be collected at designated time points throughout the study.
| Arm | Type | Description |
|---|---|---|
| linifanib | EXPERIMENTAL | - |
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| linifanib | DRUG | QD on Day 1 of Periods 1 and 2 |
| Rifampin | DRUG | QD on Days 5-16 |
| ABT-869 | DRUG | 2.5mg \[5 mg days 1, 8 and 12. 17.5 mg on days 13 and after\] |
| ketoconazole | DRUG | 400 mg days 6-11 |
Inclusion Criteria 1. Age is greater than or equal to 18 years. 2. Subject must have a histologically or cytologically confirmed non-hematologic malignancy other than Hepatocellular Carcinoma (HCC). 3. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-2. 4. Subject must have adequate...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ABT-869, also known as linifanib, is an investigational small molecule being studied for the treatment of solid tumors. It is in Phase 1 clinical development for oncology indications. The drug is not yet approved and remains under investigation.
ABT-869 is being developed by Abbott Laboratories, a company traded under the ticker ABT. The drug is an investigational small molecule in Phase 1 clinical development for solid tumors.
ABT-869 is in Phase 1 clinical development. It is an investigational drug for solid tumors and has not been approved by regulatory authorities. One Phase 1 trial has been completed.
ABT-869 has one completed Phase 1 trial, NCT01114191, which assessed the effect of ketoconazole on the pharmacokinetics of linifanib (ABT-869) in 12 participants with solid tumors in the United States.
Yes, ABT-869 is also known as linifanib. The drug is an investigational small molecule being developed by Abbott Laboratories for the treatment of solid tumors and is currently in Phase 1 clinical development.